Bibliography
- Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-19
- Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci 2008;1138:278-98
- Ghilardi JR, Rohrich H, Lindsay TH, Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 2005;25:3126-31
- Lozano-Ondoua AN, Wright C, Vardanyan A, A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 2010;86:646-53
- Sevcik MA, Ghilardi JR, Peters CM, Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-41
- Halvorson KG, Kubota K, Sevcik MA, A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res 2005;65:9426-35
- Pezet S, McMahon SB. Neurotrophins: mediators and modulators of pain. Annu Rev Neurosci 2006;29:507-38
- Lane NE, Schnitzer TJ, Birbara CA, Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010;363(16):1521-31
- A study of Tanezumab as add-on therapy to opioid medication in patients with pain due to cancer that has spread to bone. Available from: http://clinicaltrials.gov/ct2/show/NCT00545129
- Stopeck AT, Lipton A, Body JJ, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-9
- Henry DH, Costa L, Goldwasser F, Randomized, double-blind study of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32
- Fizazi K, Carducci M, Smith M, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377(9768):813-22
- Cleeland CS, Patrick DL, Fallowfield L, Effects of denosumab vs zoledronic acid (ZA) on pain in patients (pts) with advanced cancer and bone metastases: an integrated analysis of 3 pivotal trials [abstract 1248P]. Presented at the 35th European Society for Medical Oncology (ESMO) Congress; 8 – 12 October 2010; Milan, Italy